Vortioxetine

Product Name:    Vortioxetine

Synonyms:    Trintellix (vortioxetine);Vortioxetine(Lu AA21004);1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE-HCL;Vortioxetin;Vortioxetine, >=99%;Vortioxetine ?LuAA21004 ? 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine;Lu AA 21004;Vortioxetine

CAS:    508233-74-7

MF:    C18H22N2S

MW:    298.45

EINECS:    823-919-6

Product Categories:    Inhibitors;5-HT antagonist;Serotonin transporter inhibitor

Vortioxetine is a new drug for treating depression, jointly developed and researched by the Danish Lundbeck (Lundbeck) and Japanese Takeda.  In September 30, 2013, It is approved by the U.S. Food and Drug Administration (FDA) to enter into market with the brand name of Brintellix, for Major Depression Disorder (MDD) treatment.

In October 2013, the European Medicines Agency (EMA)’s subordinate agency: Committee for Medicinal Products for Human Use (CHMP) recommended that vortioxetine for the treatment of severe depression should be licensed in the European market and be launched into  the  European market in January 2014.

MDD features mood changes and a series of other symptoms, which have a great impact on the patient's ability to work, sleep, study, eat and enjoy the current happiness. Depressive symptoms can recur many times in life, but some patients may experience only once.